Showing results (31-40 of 44) with videos related to
Sort By:
Pageof 5
Blood Cells, Molecules & Diseases|June 18, 2002
Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trialAurelio Maggio, Gennaro D'Amico, Alberto Morabito, et al.Journal of Magnetic Resonance Imaging : JMRI|June 27, 2009
Multicenter validation of the magnetic resonance T2* technique for segmental and global quantification of myocardial ironAnna Ramazzotti, Alessia Pepe, Vincenzo Positano, et al.Blood Cells, Molecules & Diseases|May 1, 2013
Long-term treatment with deferiprone enhances left ventricular ejection function when compared to deferoxamine in patients with thalassemia majorAldo Filosa, Angela Vitrano, Paolo Rigano, et al.Blood Cells, Molecules & Diseases|August 17, 2011
Iron chelation therapy in thalassemia major: a systematic review with meta-analyses of 1520 patients included on randomized clinical trialsAurelio Maggio, Aldo Filosa, Angela Vitrano, et al.American Journal of Hematology|May 25, 2012
Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patientsAurelio Maggio, Angela Vitrano, Gaetano Lucania, et al.Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|January 18, 2013
Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapyAlessia Pepe, Antonella Meloni, Giuseppe Rossi, et al.Haematologica|October 2, 2010
Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imagingAlessia Pepe, Antonella Meloni, Marcello Capra, et al.Blood Cells, Molecules & Diseases|January 23, 2013
Serial echocardiographic left ventricular ejection fraction measurements: a tool for detecting thalassemia major patients at risk of cardiac deathAurelio Maggio, Angela Vitrano, Giuseppina Calvaruso, et al.Hemoglobin|February 16, 2008
Standardized T2* map of a normal human heart to correct T2* segmental artefacts; myocardial iron overload and fibrosis in thalassemia intermedia versus thalassemia major patients and electrocardiogram changes in thalassemia major patientsAnna Ramazzotti, Alessia Pepe, Vincenzo Positano, et al.British Journal of Haematology|February 25, 2009
Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trialAurelio Maggio, Angela Vitrano, Marcello Capra, et al.Pageof 5